GBT Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $52.1 million, a 41% increase year over year Oxbryta sNDA and NDA for pediatric label expansion accepted by FDA for priority review; PDUFA target...
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
November 04, 2021 09:05 ET
|
Global Blood Therapeutics, Inc.
Accepted Abstracts Include Real-World Experience with Oxbryta® (voxelotor) and Phase 1 Data on GBT021601 and Inclacumab SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood...
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
November 01, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy...
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
October 28, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
Company to also host R&D Day on Thursday, November 11 in New York City and via video webcast SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT)...
GBT Announces New Employment Inducement Grants
October 07, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2021, the compensation committee of GBT’s board...
GBT Announces Participation at the Cantor Global Healthcare Conference
September 20, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor...
GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat die Gründung der GBT Foundation bekannt gegeben. Die Stiftung agiert als...
GBT inaugure sa Fondation, pour améliorer la santé et le bien-être de communautés de patients défavorisés le monde
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., 14 sept. 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics Inc. (GBT) (NASDAQ: GBT) a annoncé le lancement de sa Fondation, une organisation dédiée à améliorer la santé...
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
September 14, 2021 11:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a 501(c)(3) organization and source of...
GBT Announces New Employment Inducement Grants
September 09, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2021, the compensation committee of GBT’s...